Commentary & Perspectives

The Role of Human Leukocyte Antigens in Reducing Lung Cancer Risk

With findings that human leukocyte antigen-II (HLA-II) heterozygosity is associated with reduced risk of developing lung cancer, with particular benefits to smokers, Mount Sinai researchers add evidence to the theory of the immune system's protective function against cancer.

  • by

  • February 5, 2025

  • 1 min

Share

Mount Sinai researchers have identified that heterozygosity of human leukocyte antigen-II (HLA-II) is linked to a decreased risk of lung cancer, especially among smokers. This study reinforces the hypothesis that the immune system plays a critical protective role against the development of cancer. The findings could have significant implications for understanding the genetic factors influencing lung cancer risk and the interplay between immune response and carcinogenesis.

Related Content

Dana-Farber Research Supports FDA Approval of Sevabertinib for HER2-Mutant Lung Cancer

The US Food and Drug Administration has approved sevabertinib, an oral targeted therapy for adult patients with non-small-cell lung cancer (NSCLC) whose tumors harbor certain HER2 (also called ERBB2) mutations and who have previously received chemotherapy or immunotherapy.

  • by

  • November 20, 2025

  • 3 min
Dana-Farber Research News 9.01.2024

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from August 1 through August 15.

  • by

  • September 1, 2024

  • 32 min
Decline in Lung Cancer Deaths Is Linked to Increased Screening

A recent, substantial decline in lung cancer deaths is associated with earlier diagnosis of lung cancer than in the past, a new study shows.

  • by

  • March 21, 2022

  • 1 min